How Biotech M&A is Redefining the Strategic Landscape
Given current macro and regulatory headwinds, determining the optimal time to sell a biotech company is a multifaceted decision that requires careful consideration of several key factors. Hear from industry veterans Ted Love, Marc de Garidel, and Abbas Kazimi who share their insights on a new era of M&A in a panel moderated by RBC Capital Markets Analysts Dr. Brian Abrahams, Dr. Luca Issi and Dr. Gregory Renza.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of Pathfinders in Biopharma?
This episode is 25 minutes long.
When was this Pathfinders in Biopharma episode published?
This episode was published on June 23, 2023.
Can I download this Pathfinders in Biopharma episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.